Investment Rating - The report maintains an "Outperform" rating for JD Health International [2][5][17] Core Insights - JD Health's revenue for Q1 2025 reached a record high of RMB 16.65 billion, reflecting a year-over-year increase of 25.5% and a quarter-over-quarter increase of 0.8%, surpassing the full-year guidance [3][13] - The significant revenue growth is attributed to increased demand during the influenza season, growth in high-value original drugs, and higher sales of health supplements due to increased advertising investments [3][14] - The company achieved an operating profit of RMB 1.07 billion, a 119.8% increase, with an operating margin of 6.4%, leading to a net profit growth of 47.7% [3][14] - JD Health plans to focus on expanding its instant retail initiatives in 10 key cities, leveraging a hybrid B2C+O2O strategy to enhance customer engagement and operational efficiency [4][15] Financial Performance and Forecast - Revenue forecasts for FY25 and FY26 are RMB 66.6 billion and RMB 75.7 billion, representing year-over-year growth of 14.5% and 13.7% respectively [5][17] - Adjusted net profit projections are RMB 4.4 billion for FY25 and RMB 5.4 billion for FY26, with a corresponding P/E ratio of 26x and 21x [5][17] - The report emphasizes the company's strong fundamentals and maintains an optimistic outlook for the first half of 2025 and the full year [5][17]

Investment Rating - The report maintains an "Outperform" rating for JD Health International [2][18]. Core Insights - JD Health's Q1 2025 revenue reached a record high of RMB 16.65 billion, reflecting a year-over-year increase of 25.5% and a quarter-over-quarter increase of 0.8%, surpassing the full-year guidance [3][14]. - The revenue growth is attributed to increased demand during the influenza season, growth in high-value original drugs, and higher sales of health supplements due to increased advertising investments [15]. - The company achieved an operating profit of RMB 1.07 billion, a significant increase of 119.8%, with an operating margin of 6.4%, contributing to a net profit growth of 47.7% [15][18]. - JD Health plans to focus on self-operated on-demand drug delivery in 10 key cities in 2025, leveraging a hybrid B2C+O2O strategy to enhance customer stickiness and operational efficiency [4][16]. Financial Performance and Forecast - Revenue forecasts for FY25 and FY26 are RMB 66.6 billion and RMB 75.7 billion, representing year-over-year growth of 14.5% and 13.7% respectively [5][18]. - Adjusted net profit is projected at RMB 4.4 billion for FY25, reflecting a decrease of 7.3%, and RMB 5.4 billion for FY26, indicating an increase of 20.5% [5][18]. - The report estimates a P/E ratio of 26x for FY25 and 21x for FY26, indicating a favorable valuation based on the company's fundamentals [5][18]. Valuation - The DCF model estimates the equity value of JD Health at HKD 136.8 billion, corresponding to a target price of HKD 42.90 per share [8][9].

Investment Rating - The investment rating for Tencent Holdings is "Buy" and is maintained [8]. Core Insights - Tencent achieved revenue of 180 billion yuan in Q1 2025, representing a year-on-year increase of 13% and a quarter-on-quarter increase of 4%. Operating profit reached 57.6 billion yuan, up 10% year-on-year, while Non-IFRS net profit attributable to shareholders was 61.3 billion yuan, reflecting a 22% year-on-year growth. Both revenue and adjusted net profit exceeded market expectations [2][5]. Revenue Summary - The revenue growth was driven by: 1. Strong performance of evergreen games and new game launches, leading to record-high revenues in both domestic and overseas markets for Q1 [8]. 2. AI-driven enhancements and optimization of the WeChat transaction ecosystem, resulting in robust advertising growth [8]. 3. Rapid growth in AI-related revenues contributing to a year-on-year increase in cloud service revenues [8]. Profitability Summary - Tencent's profit growth has consistently outpaced revenue growth for 11 consecutive quarters, with a gross margin reaching a near-record level. The gross margin for Q1 was 55.8%, an increase of 3.2 percentage points year-on-year [8]. Capital Expenditure Summary - Capital expenditure in Q1 increased by 91.35% year-on-year to 27.476 billion yuan, accounting for approximately 15% of revenue [8].

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The company leverages AI to enhance product capabilities, leading to significant user growth and subscription increases across its product offerings [1][3] - The company has seen a substantial rise in its paid subscription user base, reaching 12.61 million by December 2024, with a year-on-year net increase of 3.5 million users [3] - Revenue projections for the company have been slightly revised upwards, with adjusted net profit forecasts for 2025 and 2026 increased to 846 million and 1.14 billion RMB respectively [4] Summary by Sections Product Performance - The company's video editing product Wink ranked 15th in the top 50 AI products in China, achieving a global monthly active user count of approximately 30 million by December 2024 [1] - The Meitu Design Studio saw a 42.53% year-on-year increase in web traffic, ranking third in domestic growth and sixth globally, with subscription users reaching 1.13 million and revenue doubling to approximately 200 million RMB in 2024 [2] - The AI visual creation tool WHEE led the AI image processing sector, with a compound weekly active user growth rate of 26.01% in Q1 2025 [2] Subscription Growth - The company’s subscription penetration rate reached 4.7% by December 2024, with expectations of exceeding 300,000 net new subscribers in Q1 2025 [3] - Traditional features within products have been enhanced with generative AI, driving user acquisition through popular functionalities [3] Financial Projections - The company’s revenue is projected to grow from 2.696 billion RMB in 2023 to 5.616 billion RMB by 2027, with a compound annual growth rate of 29.3% in 2023 and 12.7% by 2027 [9] - Adjusted net profit is expected to increase significantly, with a forecast of 368 million RMB in 2023 rising to 1.423 billion RMB by 2027 [9]

Investment Rating - The investment rating for the company is "Accumulate" and is maintained [9] Core Views - The company relies on a "3+3" strategy, balancing external mergers and internal growth, quickly entering high-growth sectors, and is expected to form three growth poles: high-voltage connectors for electric vehicles, AI optical modules, and consumer electronics acoustics. The recovery of the main business, along with the resonance of AI, new energy, and consumer electronics acoustics, combined with global capacity layout cost reduction, is expected to continuously release profits [2][6] Summary by Sections Company Overview - In Q1 2025, the company achieved revenue of 1,102.91 million USD, a year-on-year increase of 14.28%, while net profit from continuing operations was 6.24 million USD, a year-on-year decrease of 38.80% [6] Business Developments - The company showcased its CDFP SMT connectors and passive direct-connect copper cables at DesignCon 2025, achieving efficient signal transmission for PCI Express 6.0 and PCIe 7.0, which are suitable for modular architecture in data centers [9] - The company announced the launch of Smart Mobility in partnership with Saleh Suleiman Alrajhi & Sons, focusing on the EV charging market in Saudi Arabia, with the Voltaira charging station series already certified for the local market [9] - The company is optimizing its global capacity layout to respond to market changes and customer demands, enhancing manufacturing capabilities in emerging markets like Southeast Asia and India [9] Financial Projections - The company projects revenues of 4,915 million USD, 5,454 million USD, and 6,097 million USD for 2025, 2026, and 2027 respectively, with net profits of 177 million USD, 204 million USD, and 238 million USD for the same years [9]

Investment Rating - The investment rating for the company is "Buy" [6] Core Insights - The company reported a Q1 2025 revenue of $2.03 billion, a year-on-year increase of 1.3%, with a net profit of $75.76 million, down 24.2% year-on-year. The manufacturing segment generated $1.33 billion in revenue, up 5.9% year-on-year, while the retail segment saw revenue of $700 million, down 6.5% year-on-year [1][2][4] Summary by Sections Manufacturing Business - The manufacturing segment's revenue reached $1.33 billion in Q1 2025, with a shipment volume of 61.9 million pairs, reflecting a 5.3% increase year-on-year. The average selling price (ASP) was $20.00, down 2.5% year-on-year. Revenue in April 2025 increased by 10.5% year-on-year, supported by strong orders from key clients like Adidas and Asics [2][3] - The capacity utilization rate was 91% in Q1 2025, up 3 percentage points year-on-year. However, uneven capacity loading and rising labor costs pressured profit margins, leading to a gross margin of 17.7%, down 2.6 percentage points year-on-year [3] Retail Business - The retail segment reported revenue of $700 million in Q1 2025, a decrease of 6.5% year-on-year. The number of offline stores decreased to 3,437, with same-store sales down 13.9% due to weak foot traffic and store closures. Conversely, online retail revenue grew by 20% year-on-year, with live-streaming sales surging by 230% [4] - The gross margin for the retail segment was 32.7%, down 0.5 percentage points year-on-year, while the net profit margin was 2.7%, down 0.5 percentage points [4] Earnings Forecast and Valuation - The company is expected to achieve revenues of $8.5 billion, $9.0 billion, and $9.6 billion for the years 2025, 2026, and 2027, respectively, representing year-on-year growth rates of 3%, 6%, and 7%. The net profit is projected to be $410 million, $460 million, and $520 million for the same years, with corresponding growth rates of 5%, 13%, and 12% [5][11]

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company reported a Q1 2025 revenue of $2.03 billion, a year-on-year increase of 1.3%, with a net profit of $75.76 million, down 24.2% year-on-year. The manufacturing segment generated $1.33 billion in revenue, up 5.9% year-on-year, while the retail segment saw revenue of $700 million, down 6.5% year-on-year [1][2][4] Summary by Sections Manufacturing Business - The manufacturing segment's revenue reached $1.33 billion in Q1 2025, with a shipment volume of 61.9 million pairs, reflecting a 5.3% year-on-year increase. The average selling price (ASP) was $20.00, down 2.5% year-on-year. Revenue in April 2025 increased by 10.5% year-on-year, supported by strong orders from key clients like Adidas and Asics [2][3] - The capacity utilization rate was 91% in Q1 2025, up 3 percentage points year-on-year. However, uneven capacity loading and rising labor costs pressured profit margins, leading to a gross margin of 17.7%, down 2.6 percentage points year-on-year [3] Retail Business - The retail segment generated $700 million in revenue, down 6.5% year-on-year, primarily due to weak consumer demand in China and a decline in foot traffic. Online retail revenue, however, grew by 20% year-on-year, with live-streaming sales increasing by 230% [4] - The gross margin for the retail segment was 32.7%, down 0.5 percentage points year-on-year, while the net profit margin was 2.7%, down 0.5 percentage points [4] Earnings Forecast and Valuation - The company expects to achieve revenues of $8.5 billion, $9.0 billion, and $9.6 billion for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 3%, 6%, and 7%. The net profit is projected to be $410 million, $460 million, and $520 million for the same years, corresponding to growth rates of 5%, 13%, and 12% [5][11]

Investment Rating - The report assigns a "Buy" rating for the company with a target price of HKD 18.50, indicating a potential upside of 51.1% from the current price of HKD 12.24 [1][4][10]. Core Insights - The company's Q1 performance met expectations, with a year-on-year revenue increase of 11% to RMB 47 billion. The adjusted net profit rose by 13% to RMB 750 million, maintaining a net profit margin of 1.6% [2][8]. - The report highlights a recovery in double-digit growth for external integrated supply chain services, driven by differentiated solutions and an increase in wallet share from major clients. The express delivery business also saw rapid growth in order volume, although some gains were offset by industry price declines [2][8]. - The financial forecasts for 2025 show a slight increase in revenue projections, with total revenue expected to reach RMB 202.2 billion, reflecting a 0.1% upward adjustment from previous estimates [3][13]. Financial Summary - Revenue projections for 2025E are set at RMB 202,203 million, with a slight increase from the previous forecast of RMB 202,057 million [3]. - The adjusted net profit for 2025E is projected at RMB 8,350 million, a minor increase from the prior estimate of RMB 8,336 million [3]. - The gross profit margin is expected to be 10.5% for 2025, slightly down from the previous forecast of 10.7% [3][14]. Performance Metrics - The company achieved a gross profit of RMB 21,323 million in 2025E, with a gross margin of 10.5% [13][14]. - The operating profit is projected to be RMB 7,527 million for 2025E, with an adjusted operating profit margin of 3.9% [13][14]. - The report indicates a stable financial position with total assets expected to reach RMB 128,286 million by the end of 2025 [13].

Investment Rating - The report maintains a "Buy" rating for the Hong Kong stock and a "Hold" rating for the A-share, with target prices set at HKD 11.7 and CNY 19.6 respectively [7][9][10]. Core Insights - The company's 1Q25 performance slightly exceeded expectations, with total revenue reaching CNY 381 million, representing a year-on-year increase of 129.9% and a quarter-on-quarter increase of 22.3% [7][10]. - The revenue from the drug Oubatinib was CNY 311 million, up 89.2% year-on-year and 1.2% quarter-on-quarter, leading to an upward revision of the annual revenue growth guidance for Oubatinib from 30% to 35% [7][10]. - The report highlights the strong sales growth of Oubatinib, driven by the increasing market share in the r/r CLL/SLL segment and the expansion of indications [7][10]. Financial Performance Summary - 1Q25 net profit attributable to shareholders was CNY 17.97 million, which is an improvement compared to previous losses, attributed to better-than-expected revenue and lower sales and administrative expenses [7][10]. - The gross margin for product sales improved to 88.4%, up from 85.3% in 1Q24 and 87% in 4Q24, indicating enhanced operational efficiency [7][10]. - The report projects significant revenue growth for the coming years, with expected revenues of CNY 1.45 billion in 2025, reflecting a 43.9% year-on-year increase [9][10]. Research and Development Progress - The company is advancing two TYK2 inhibitors, with ongoing clinical trials for ICP-332 and ICP-448, expected to yield important data in the coming years [7][10]. - Key upcoming catalysts include new indication approvals and significant data readouts for Oubatinib and other products [7][10]. Market Position and Valuation - The current market capitalization is approximately HKD 20.066 billion, with a recent average trading volume of HKD 121 million over the past three months [2][4]. - The stock has a 52-week price range of HKD 4.2 to HKD 11.0, indicating potential for growth based on the target price [2][4].

Investment Rating - The report does not explicitly state an investment rating for Samsonite, but it indicates a challenging environment for revenue and profit performance [1][9]. Core Insights - In 1Q25, Samsonite's net sales decreased by 4.5% year-on-year to $797 million, primarily due to weak demand in North America and China, along with a high base from the previous year [2][9]. - The company aims to maintain gross margin levels despite a 100 basis points decline to 59.4% in 1Q25, attributed to changes in geographic sales mix [2][9]. - Adjusted EBITDA fell by 20.9% year-on-year, leading to an adjusted EBITDA margin of 18.8%, down 280 basis points [2][9]. - Adjusted net income decreased by 40.3% year-on-year, driven by lower EBITDA, increased depreciation, net interest expenses, and a higher effective tax rate [2][9]. - The company reported a negative adjusted free cash flow of $41 million in 1Q25, reversing from a positive position due to EBITDA decline and increased net working capital [2][9]. Regional Performance - Sales in Asia and North America were weak, with Asia's revenue down 7% and North America's down 8% [3][10]. - Europe showed strong growth with a 4.4% increase in net sales, supported by positive growth across all core brands [3][10]. - Latin America’s sales remained flat, with a notable decline in Mexico offset by strong growth in Chile [3][10]. Channel Performance - The Direct-to-Consumer (DTC) channel accounted for 38.2% of revenue in 1Q25, with e-commerce contributing 10.6% and offline retail 27.5% [4][11]. - The offline retail business saw a decline of 2.6%, primarily due to reduced customer traffic, while wholesale business declined by 6.1% [4][11]. Tariff Policy and Mitigation Strategies - The U.S. tariff policy remains unclear, causing caution among consumers and wholesale customers [5][12]. - The company has reduced its sourcing from China to 14% and plans to further decrease this by year-end, employing various strategies to mitigate potential tariff impacts [5][12]. Future Guidance - Management expects 2Q25 net sales growth to be similar to 1Q25, with a mid-single-digit decline in net revenue on a constant currency basis [6][13]. - Long-term growth is anticipated to be supported by strong travel trends, despite short-term macroeconomic uncertainties affecting consumer demand [6][13].